Acer Therapeutics Inc (ACER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
51
About the Report
About the Report
Summary
Acer Therapeutics Inc (Acer), formerly Opexa Therapeutics Inc is a pharmaceutical company that offers acquisition, development and commercialization of therapies for patients with serious rare diseases. The company offers treatment of autoimmune disorders, rheumatoid arthritis, diabetes and heart failure. Its late-stage clinical pipeline includes drug candidates for severe genetic disorders such as EDSIVO and celiprolol for vascular Ehlers-Danlos syndrome, and ACER-001, a fully taste-masked, immediate release formulation of sodium phenylbutyrate for urea cycle disorders. It uses T-cell technology platform for the development of patient-specific T-cell therapies. The company operates manufacturing facility, and research and development facilities in the US and Canada. Acer is headquartered in Newton, Massachusetts, the US.
Acer Therapeutics Inc (ACER)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Acer Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acer Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acer Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Acer Therapeutics Raises USD15.7 Million in Venture Financing 12
Acer Therapeutics to Raise USD10 Million in Venture Financing 13
Acer Therapeutics Raises USD8.2 Million in Financing 14
Acer Therapeutics Raises USD2 Million in Venture Financing 15
Licensing Agreements 16
Acer Therapeutics Enters into Licensing Agreement with AP-HP 16
Acer Therapeutics Enters into Licensing Agreement with Baylor College of Medicine 17
Equity Offering 18
Acer Therapeutics Raises USD46 Million in Public Offering of Shares 18
Acer Therapeutics Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares for USD12.6 Million 20
Opexa Therapeutics Plans to Raise Funds through Public Offering of Shares 22
Opexa Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 23
Opexa Therapeutics Raises USD13.8 Million in Rights Offering of Units 25
Opexa Therapeutics Completes Public Offering Of Shares For USD 8 Million 27
Opexa Therapeutics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For USD 19 Million 29
Opexa Therapeutics Completes Private Placement Of Shares For USD 0.5 Million 30
Opexa Therapeutics Completes Private Placement Of Units For USD 3.2 Million 31
Opexa Therapeutics Private Placement Of Common Stock For USD 0.5 Million 33
Opexa Therapeutics Files Prospectus For Public Offering Of Shares 34
Opexa Therapeutics Completes First Tranche Of Private Placement Of Shares For USD 0.05 Million 35
Debt Offering 37
Opexa Therapeutics Raises USD4.1 Million in Private Placement of Notes 37
Acquisition 38
Opexa Therapeutics Acquires Acer Therapeutics in Reverse Takeover Transaction 38
Acer Therapeutics Inc-Key Competitors 39
Acer Therapeutics Inc-Key Employees 40
Acer Therapeutics Inc-Locations And Subsidiaries 41
Head Office 41
Recent Developments 42
Financial Announcements 42
Aug 13, 2018: Acer Therapeutics reports second quarter 2018 financial results and provides corporate update 42
May 14, 2018: Acer Therapeutics Announces First Quarter 2018 Financial Results 44
Mar 07, 2018: Acer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 45
Nov 13, 2017: Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 47
Corporate Communications 48
Oct 12, 2017: Acer Therapeutics Welcomes Two New Members to its Board of Directors 48
Oct 05, 2017: Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer 49
Product Approvals 50
Sep 25, 2017: Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Figure
List of Figures
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acer Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acer Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acer Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acer Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acer Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acer Therapeutics Raises USD15.7 Million in Venture Financing 12
Acer Therapeutics to Raise USD10 Million in Venture Financing 13
Acer Therapeutics Raises USD8.2 Million in Financing 14
Acer Therapeutics Raises USD2 Million in Venture Financing 15
Acer Therapeutics Enters into Licensing Agreement with AP-HP 16
Acer Therapeutics Enters into Licensing Agreement with Baylor College of Medicine 17
Acer Therapeutics Raises USD46 Million in Public Offering of Shares 18
Acer Therapeutics Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares for USD12.6 Million 20
Opexa Therapeutics Plans to Raise Funds through Public Offering of Shares 22
Opexa Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 23
Opexa Therapeutics Raises USD13.8 Million in Rights Offering of Units 25
Opexa Therapeutics Completes Public Offering Of Shares For USD 8 Million 27
Opexa Therapeutics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For USD 19 Million 29
Opexa Therapeutics Completes Private Placement Of Shares For USD 0.5 Million 30
Opexa Therapeutics Completes Private Placement Of Units For USD 3.2 Million 31
Opexa Therapeutics Private Placement Of Common Stock For USD 0.5 Million 33
Opexa Therapeutics Files Prospectus For Public Offering Of Shares 34
Opexa Therapeutics Completes First Tranche Of Private Placement Of Shares For USD 0.05 Million 35
Opexa Therapeutics Raises USD4.1 Million in Private Placement of Notes 37
Opexa Therapeutics Acquires Acer Therapeutics in Reverse Takeover Transaction 38
Acer Therapeutics Inc, Key Competitors 39
Acer Therapeutics Inc, Key Employees 40
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.